Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D84EGX
|
|||
| Drug Name |
AT-342
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Crigler-Najjar syndrome [ICD-11: 5C58.00] | Phase 1/2 | [1] | |
| Company |
Audentes Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | UDP-glucuronosyltransferase 1A1 (UGT1A1) | Target Info | Replacement | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03223194) Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.